United Therapeutics (UTHR) Revenue Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Revenue Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 5.56% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 7.01% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 3.37% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 8.00% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 4.95% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 7.50% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 20.59% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 9.51% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 28.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.51% |
| Mar 31, 2026 | 15.52% |
| Dec 31, 2025 | 17.15% |
| Sep 30, 2025 | 15.71% |
| Jun 30, 2025 | 19.59% |
| Mar 31, 2025 | 19.81% |
| Dec 31, 2024 | 21.02% |
| Sep 30, 2024 | 18.97% |
| Jun 30, 2024 | 16.99% |
| Mar 31, 2024 | 21.37% |
| Dec 31, 2023 | 16.89% |
| Sep 30, 2023 | 17.04% |
| Jun 30, 2023 | 18.11% |
| Mar 31, 2023 | 12.47% |
| Dec 31, 2022 | 16.47% |
| Sep 30, 2022 | 8.72% |
| Jun 30, 2022 | 7.71% |
| Mar 31, 2022 | 8.40% |
| Dec 31, 2021 | 2.87% |
| Sep 30, 2021 | 2.52% |